Intangible Assets, Net - ProstaGene (Details) - USD ($) $ in Thousands, shares in Millions |
1 Months Ended | 3 Months Ended | ||||
---|---|---|---|---|---|---|
May 19, 2022 |
Mar. 31, 2021 |
Feb. 28, 2021 |
May 31, 2022 |
May 31, 2021 |
May 31, 2020 |
|
Loss Contingencies [Line Items] | ||||||
Shares subject to arbitration | 3.1 | |||||
Non cash charge | $ 800 | |||||
Impairment charge, reversal of accumulated amortization | $ 2,200 | |||||
Impairment charge, gross | $ 12,200 | |||||
Intangible Assets, Net (Excluding Goodwill) | $ 132 | $ 1,653 | ||||
Patents | ||||||
Loss Contingencies [Line Items] | ||||||
Intangible Assets, Net (Excluding Goodwill) | $ 3,500 | $ 4,600 | $ 4,600 |
X | ||||||||||
- Definition The number of shares subject to arbitration in connection with acquisition of intangible asset. No definition available.
|
X | ||||||||||
- Definition The portion of the intangible asset impairment expense recognized during the period that is attributable to the original gross value/cost of the asset. No definition available.
|
X | ||||||||||
- Definition The portion of the intangible asset impairment expense recognized during the period that reflects reversal of accumulated amortization through impairment date. No definition available.
|
X | ||||||||||
- Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Details
|